Mr. Speaker, I am pleased to rise in the House to speak to this bill. This is kind of a magical moment. Every now and then, a rare bill brings Parliament together to pass a law that is good for all Canadians. I believe that is what is happening now.
However, I have two concerns about this bill. The first is that we have to make sure the bill will be properly enforced. Passing a bill is all well and good, but it has to be enforced. Unfortunately, in many areas, the devil is in the enforcement details. The government has good intentions, but, unfortunately, it does not provide the tools to properly enforce the law. The unfortunate events that occurred in Walkerton are an example of that.
My second concern is about generic drugs. Most of them are not currently subject to clinical trials. Basically, the brand-name drugs go through clinical trials, and the generics just copy them. Unfortunately, too often, there are quality differences between the brand-name drugs and their generic equivalents. It has been found that imported generic drugs are often dangerous.
I would like the NDP health critic to tell me whether this bill will protect us from such situations.